No Data
Institutions Profited After AbCellera Biologics Inc.'s (NASDAQ:ABCL) Market Cap Rose US$92m Last Week but Individual Investors Profited the Most
AI-focused Drug Discovery Firms Rise as FDA Phases Out Animal Testing
AbCellera to Participate at Upcoming Investor Conferences in May and June
Press Release: AbCellera to Report First Quarter 2025 Financial Results on May 8, 2025
AbCellera Announces Presentation of In Vivo Data on PSMA X CD3 T-Cell Engagers at AACR 2025
Insider Purchase: Director at $ABCL Buys 25,000 Shares
Buy n Die Together❤ :
73610841 : Adrian Nathaniel carter, I can’t tag him and we’re Facebook friends, does anyone know why?
Seth Beaty : Though you know if you bet against Cathie Wood, you’ll probably make money.
Rob banks : is there an ETF for this ai medical sector?
Chak : is it goid time yo
get into TEM ?
View more comments...